Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for nine companies, including Hemei Pharmaceutical, which is seeking to list on the Hong Kong Stock Exchange. The CSRC is requesting detailed explanations regarding the company's previous A-share listing guidance and its future plans for A-share listing [1][2]. Group 1 - The CSRC has requested Hemei Pharmaceutical to clarify its previous A-share listing guidance and whether it plans to continue with the A-share listing, including any significant impacts on the current listing process [1][2]. - Hemei Pharmaceutical was established in 2002 and is an innovative biopharmaceutical company focused on discovering and developing small molecule drugs for autoimmune diseases and tumors, maintaining a leading position in the development of treatments for psoriasis, Behçet's disease, and inflammatory bowel disease [2]. - As of May 21, 2025, Hemei Pharmaceutical has developed seven small molecule drug candidates targeting high unmet needs in autoimmune and tumor diseases, with four candidates in Phase II, III clinical trials, or NDA stages for twelve indications [2]. Group 2 - Hemei Pharmaceutical's core product, Mufemilast, is a novel small molecule phosphodiesterase 4B (PDE4B) protein expression blocker and PDE4 inhibitor, showing potential for treating a wide range of autoimmune diseases. According to Frost & Sullivan, Mufemilast may be a first-in-class drug with dual mechanisms of action [2].
新股消息 和美药业拟港股上市 中国证监会要求补充说明前期进行A股上市辅导备案的详细情况等
Jin Rong Jie·2025-08-01 15:46